Literature DB >> 34010392

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.

David C Bishop1,2,3,4, Leighton E Clancy1,5, Renee Simms1,2,5, Jane Burgess1,2,5, Geetha Mathew1,5, Leili Moezzi1,5, Janine A Street1,5, Gaurav Sutrave1,2,3,4, Elissa Atkins3, Helen M McGuire6,7,8, Brian S Gloss1, Koon Lee1,2, Wei Jiang1,2, Karen Maddock3, Georgia McCaughan2,3, Selmir Avdic1,5, Vicki Antonenas5, Tracey A O'Brien9,10,11, Peter J Shaw12,13, David O Irving14,15, David J Gottlieb1,2,3,4,5, Emily Blyth1,2,3,4,5, Kenneth P Micklethwaite1,2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34010392     DOI： 10.1182/blood.2021010813

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  20 in total

Review 1.  Gene editing to enhance the efficacy of cancer cell therapies.

Authors:  Tara Murty; Crystal L Mackall
Journal:  Mol Ther       Date:  2021-10-18       Impact factor: 11.454

2.  High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.

Authors:  Brian R Shy; Vivasvan S Vykunta; Alvin Ha; Alexis Talbot; Theodore L Roth; David N Nguyen; Wolfgang G Pfeifer; Yan Yi Chen; Franziska Blaeschke; Eric Shifrut; Shane Vedova; Murad R Mamedov; Jing-Yi Jing Chung; Hong Li; Ruby Yu; David Wu; Jeffrey Wolf; Thomas G Martin; Carlos E Castro; Lumeng Ye; Jonathan H Esensten; Justin Eyquem; Alexander Marson
Journal:  Nat Biotechnol       Date:  2022-08-25       Impact factor: 68.164

3.  Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy.

Authors:  Axel Schambach; Michael Morgan; Boris Fehse
Journal:  Mol Ther       Date:  2021-08-24       Impact factor: 12.910

4.  Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.

Authors:  Jaitip Tipanee; Ermira Samara-Kuko; Thierry Gevaert; Marinee K Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2022-06-16       Impact factor: 12.910

Review 5.  Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.

Authors:  Alexander Michels; Naphang Ho; Christian J Buchholz
Journal:  Mol Ther       Date:  2022-05-20       Impact factor: 12.910

Review 6.  Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.

Authors:  Dimitrios L Wagner; Ulrike Koehl; Markus Chmielewski; Christoph Scheid; Renata Stripecke
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 7.  Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

Authors:  Mohamed Abou-El-Enein; Magdi Elsallab; Gerhard Bauer; Barbara Savoldo; Steven A Feldman; Andrew D Fesnak; Helen E Heslop; Peter Marks; Brian G Till
Journal:  Blood Cancer Discov       Date:  2021-08-03

8.  Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.

Authors:  Kenneth P Micklethwaite; Kavitha Gowrishankar; Brian S Gloss; Ziduo Li; Janine A Street; Leili Moezzi; Melanie A Mach; Gaurav Sutrave; Leighton E Clancy; David C Bishop; Raymond H Y Louie; Curtis Cai; Jonathan Foox; Matthew MacKay; Fritz J Sedlazeck; Piers Blombery; Christopher E Mason; Fabio Luciani; David J Gottlieb; Emily Blyth
Journal:  Blood       Date:  2021-10-21       Impact factor: 25.476

9.  NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.

Authors:  Alejandra Leivas; Antonio Valeri; Laura Córdoba; Almudena García-Ortiz; Alejandra Ortiz; Laura Sánchez-Vega; Osvaldo Graña-Castro; Lucía Fernández; Gonzalo Carreño-Tarragona; Manuel Pérez; Diego Megías; María Liz Paciello; Jose Sánchez-Pina; Antonio Pérez-Martínez; Dean A Lee; Daniel J Powell; Paula Río; Joaquín Martínez-López
Journal:  Blood Cancer J       Date:  2021-08-14       Impact factor: 11.037

10.  New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.

Authors:  Madiha Iqbal; Bipin N Savani; Mehdi Hamadani
Journal:  EJHaem       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.